# abcam

## Product datasheet

## Anti-HIV protease antibody [1696] ab8327

8 References 1 Image

Overview

Product name Anti-HIV protease antibody [1696]

**Description** Mouse monoclonal [1696] to HIV protease

Host species Mouse

**Specificity** The antibody recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2). The antibody

does not react with the precursor.

Tested applications Suitable for: Dot blot

Immunogen Recombinant full length protein corresponding to HIV protease. Bacterially expressed full-length

HIV-1 protease.

Database link: P03366

**Properties** 

Form Liquid

Storage instructions Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long

term. Avoid freeze / thaw cycle.

Storage buffer pH: 7.40

Preservative: 0.098% Sodium azide

Constituent: 99% PBS

Purity Protein A purified

**Clonality** Monoclonal

Clone number 1696

**Myeloma** unknown

**Isotype** IgG1

**Applications** 

**The Abpromise guarantee** Our **Abpromise guarantee** covers the use of ab8327 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

1


Application	Abreviews	Notes
Dot blot		Use at an assay dependent concentration.

### **Target**

#### Relevance

The HIV1 core consists of a viral genome housed within a conical viral capsid that is generated during virion maturation. Human immunodeficiency virus type 1 (HIV1) matures after the viral protease processes the Gag and Pol polyproteins at 10 substrate locations. The protease of HIV1 is an aspartic protease and is functional only as a dimer; dimerization results in the formation of a binding cleft in which each of the two catalytic aspartic acids in which each monomer contributes each of the 2 catalytic aspartic acids. Because the protease is active only as a dimer, two of the GagPol precursors must themselves dimerize during virus assembly so that their protease domains can dimerize, become active, and process the precursors. Both the order and kinetics of cleavage as well as the extent of precursor processing appear to be critical steps in the generation of fully infectious, appropriately assembled viral particles. Inhibition of HIV-1 protease represents an important avenue for antiviral therapy. Currently available combination chemotherapy with reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs) for human immunodeficiency virus type 1 (HIV1) infection and AIDS have been shown to suppress the replication of HIV1 and extend the life expectancy of HIV1 infected individuals.

#### **Images**



Dot blot analysis of ab8327. The total amount of ab8327 spotted on the nitrocellulose membrane are indicated in left column.

Lane 1: ab8327; 0.2 µg/ml

Lane 2: ab8327; 1.0 µg/ml

Lane 3: ab8327; 2.0 µg/ml

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

## Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery

- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <a href="https://www.abcam.com/abpromise">https://www.abcam.com/abpromise</a> or contact our technical team.

## Terms and conditions

• Guarantee only valid for products bought direct from Abcam or one of our authorized distributors